Soleno Therapeutics, Inc.

NASDAQ•SLNO

CEO: Dr. Anish Bhatnagar M.D.

Sector: Healthcare

Industry: Biotechnology

Listing Date: 2014-11-13

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

Contact Information

203 Redwood Shores Parkway, Suite 500, Redwood City, CA, 94065, United States

650-213-8444

soleno.life

Market Cap

$2.73B

P/E (TTM)

134.6

Dividend Yield

52W High

$90.32

52W Low

$29.43

52W Range

38%

Rank51Top 71.3%

3.0

F-Score

Modified Piotroski Analysis

Based on 10-year fundamentals

Weak • 3 / 9 points

Scoring Range (0-9)

8-9: Excellent Value

6-7: Strong Fundamentals

4-5: Average Quality

0-3: Weak Performance

Data Period: 2016-2025

Financial Dashboard

Q4 2025 Data

Revenue

$91.73M+0.00%

4-Quarter Trend

EPS

$0.96+0.00%

4-Quarter Trend

FCF

$48.65M+0.00%

4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

First Year Profitability Achieved Net income $20.9M for 2025 after VYKAT XR approval in March; cash flow from operations $46.8M provided.

VYKAT XR Drives Revenue Product revenue reached $190.4M in 2025 following FDA approval; zero revenue reported in prior year.

R&D Spending Decreases Research and development expenses fell 48% to $40.6M in 2025 post-NDA submission; SG&A increased 25%.

Strong Cash Position Maintained Total assets grew to $563.8M by year-end 2025, supported by $215.7M in net stock sales proceeds.

Risk Factors

Limited Commercialization History Financial results depend primarily on successful launch of sole product, VYKAT XR; sustained profitability uncertain.

Future Capital Needs Exist May require additional funding to support operations and scale sales; raising capital risks dilution or unfavorable terms.

Intellectual Property Challenges Patent litigation is prevalent; ability to maintain competitive advantage relies on strong, broad intellectual property protection.

Regulatory and Market Acceptance VYKAT XR must achieve broad market acceptance by payers and physicians; regulatory hurdles remain for international sales.

Outlook

Continued VYKAT XR Launch Focus remains on successful launch, selling, and supporting VYKAT XR across the US market and distribution channels.

International Expansion Pursued Addressing EMA comments for EU Marketing Authorization Application; final commercialization strategy outside US pending.

Manage Growth and Operations Must continue improving managerial, operational, and financial systems to effectively manage rapid employee and operational growth.

Peer Comparison

Revenue (TTM)

LEGN

$1.03B

+64.2%

APLS

$1.00B

+28.5%

RARE

$672.72M

+20.1%

Gross Margin (Latest Quarter)

SLNO

99.1%

+0.0pp

RARE

86.0%

-2.4pp

APLS

85.1%

+11.7pp

Key Metrics

Symbol	Market Cap	P/E (TTM)	ROE (TTM)	Debt to Assets
PRAX	$6.85B	-24.1	-58.7%	0.0%
CELC	$6.07B	-37.3	-203.2%	41.9%
CNTA	$5.90B	-27.2	-50.7%	1.1%

Long-Term Trends

Last 4 Quarters

Revenue

Net Income

Operating Cash Flow

4Q Revenue CAGR

N/M

Revenue Volatile

4Q Net Income CAGR

N/M

Profitability Shift

Cash Flow Stability

50%

Cash Flow Needs Attention

Deep Research

Next earnings:May 5, 2026

EPS:-

Revenue:-

Financials

Earnings Calls

Reports

News

Income Statement

Balance Sheet

Cash Flow Statement

Ratios

% Chg.

Income Statement	LTM

No Data